Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MITF | O75030 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
| ▸ | KDM5C | P41229 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15065576 | 0.81 | SCN5A (0.45) | MCHR1KDM4ENPC1ALDH1A1RAB9A | |
| SCHEMBL13050260 | 0.75 | NPC1 (0.53) | MCHR1KDM4EMEN1NPC1MITF | |
| SCHEMBL974506 | 0.75 | HDAC1 (0.33) | MCHR1KDM4EMEN1NPC1MITF | |
| SCHEMBL2707031 | 0.72 | MCHR1 (0.49) | MCHR1KDM4EMEN1NPC1MITF | |
| SCHEMBL10129490 | 0.72 | SSTR4 (0.48) | SSTR4KDM4EMEN1NPC1ALDH1A1 | |
| SCHEMBL974075 | 0.70 | KDM4E (0.39) | KDM4EMEN1NPC1ALDH1A1RAB9A | |
| SCHEMBL13050251 | 0.70 | RAB9A (0.51) | MCHR1KDM4EMEN1NPC1ALDH1A1 | |
| SCHEMBL13050269 | 0.70 | APP (0.46) | MCHR1KDM4EMEN1NPC1MITF | |
| SCHEMBL1500059 | 0.70 | PIK3CG (0.55) | MCHR1KDM4EMEN1NPC1MITF | |
| SCHEMBL13050280 | 0.68 | APP (0.49) | MCHR1KDM4EMEN1NPC1MITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2235016-B1 | AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2013-09-18 | — | — | EP | disclosed |
| US-8394820-B2 | N-azabicyclic carboxamide derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-03-12 | — | — | US | disclosed |
| US-20110009444-A1 | N-AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009444-A1 | N-AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | XDH, NQO2, SLC28A2 | MCHR1 3657/4885SSTR4 1347/4885KDM4E 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.